This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes
by Zacks Equity Research
Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.
Alnylam's Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
Here's Why Hold Strategy is Apt for Acadia Healthcare Stock
by Zacks Equity Research
Acadia Healthcare (ACHC) continues to benefit from increasing demand for telehealth services, strategic buyouts and solid financial position.
Amarin (AMRN) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio
by Zacks Equity Research
ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.
Centene's Contract Renewal to Aid Medicaid Members in Indiana
by Zacks Equity Research
Centene's (CNC) subsidiary MHS gets a contract renewal through which it will be able to efficiently serve its Medicaid members in Indiana.
Encompass Health Forms JV to Efficiently Serve South Carolina
by Zacks Equity Research
Encompass Health (EHC) and MUSC Health intend to offer improved healthcare services in South Carolina through a joint venture.
Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study
by Zacks Equity Research
Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.
Emergent BioSolutions' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease designation on Editas' (EDIT) experimental candidate EDIT-301, which is being developed for treating sickle cell disease.
Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline
by Zacks Equity Research
Bristol Myers (BMY) enters into an agreement to acquire privately-held Forbius in a bid to boost its pipeline of immunotherapies.
Unity Biotechnology (UBX) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Looking for a Growth Stock? 3 Reasons Why Emergent Biosolutions (EBS) is a Solid Choice
by Zacks Equity Research
Emergent Biosolutions (EBS) possesses solid growth attributes, which could help it handily outperform the market.
Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod
by Zacks Equity Research
Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. The company's efforts to develop its pipeline are impressive.
Axsome's NDA Filing for Migraine Candidate in Q4 on Track
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.
Sorrento to Buy Privately-Held SmartPharm to Boost Pipeline
by Zacks Equity Research
Sorrento (SRNE) signs agreement to acquire SmartPharm Therapeutics in exchange for its common stock worth up to $19.4 million.
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
by Zacks Equity Research
BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.
Pluristem Completes Enrollment in Phase I Hematology Study
by Zacks Equity Research
Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.
Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors
by Zacks Equity Research
Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.
MannKind (MNKD) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
CRISPR Therapeutics (CRSP) Surges: Stock Moves 6% Higher
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.